SkinHealth Systems Inc.
SKIN Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$10.12
KIRA · Stoqly’s AI analyst, in plain words
- SkinHealth Systems Inc. had $301M of revenue in fiscal 2025, down 10.0% on the year before. Over five years, revenue changed +20.4% a year on average.
- Its operating margin was −6.9%, up 13.4 pts: of every 100 in sales, about −7 is left after running the business.
- SkinHealth Systems Inc. lost $9.5M in fiscal 2025.
- Free cash flow was $37.2M in fiscal 2025, 12.4% of revenue.
- SkinHealth Systems Inc. returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 4.7%.
Market cap
$1.3B
P/E
—
Revenue
$301M
Net income
−$9.5M
Free cash flow
$37.2M
Operating margin
−6.9%
SkinHealth Systems Inc. in 30 seconds · fiscal 2025
Are sales growing?
−10.0%
No. Sales fell 10.0% last year.
Does it make a profit?
−3.2%
No. It lost money last year.
Does profit turn into cash?
12.4%
Yes. 12.4% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What SkinHealth Systems Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- SkinHealth Systems Inc.
- CIK
- 0001818093
SkinHealth Systems Inc. · SKIN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $260M | $366M | $398M | $334M | $301M |
| Revenue growth | 118.4% | 40.7% | 8.8% | −16.0% | −10.0% |
| Gross margin | 68.6% | 68.0% | 39.0% | 54.5% | 65.3% |
| Operating margin | −15.4% | −7.1% | −32.9% | −20.3% | −6.9% |
| Net income | −$379M | $44.2M | −$100M | −$29.1M | −$9.5M |
| Net margin | −145.6% | 12.1% | −25.2% | −8.7% | −3.2% |
| Diluted EPS | −$3.71 | −$0.23 | −$0.76 | −$0.36 | −$0.16 |
| Cash | |||||
| Cash from operations | −$28.4M | −$107M | $21.8M | $16.1M | $37.5M |
| Capital expenditure | $11.2M | $10.8M | $3.8M | $0.8M | $0.3M |
| Free cash flow | −$39.6M | −$117M | $17.9M | $15.4M | $37.2M |
| FCF margin | −15.2% | −32.1% | 4.5% | 4.6% | 12.4% |
| Share buybacks | $0.0M | $160M | $30.2M | $0.0M | $0.0M |
| Share count change | 197.8% | 45.4% | −11.3% | 8.2% | −4.7% |
| Debt and strength | |||||
| Cash and short-term investments | $902M | $568M | $523M | $370M | $233M |
| Debt incl. finance leases | — | — | — | $552M | — |
| Shareholders' equity | $298M | $167M | $59.4M | $51.8M | $61.1M |
| Current ratio | 13.1x | 10.9x | 6.1x | 7.0x | 1.7x |
| Interest coverage | −3.4x | −1.9x | −9.6x | −6.5x | −1.1x |
| Returns and quality | |||||
| Return on capital | — | — | — | −22.9% | — |
| Return on equity | −283.2% | 19.0% | −88.4% | −52.3% | −16.9% |
| Return on tangible equity | −320.1% | — | — | — | — |
| Piotroski F-score | 3 | 3 | 4 | 6 | 6 |
| Altman Z'' | 4.0 | 3.5 | 1.6 | 0.9 | −1.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
SkinHealth Systems Inc. · SKIN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.12 a share, the company is worth $1.3B.
Source: SEC EDGAR XBRL filings (CIK 0001818093). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.